Young Pharmaceuticals Discloses 5.22% Azitra Stake, Plans Board Engagement
AZTR sits 22% above its 52-week low of $0.518 on light trading volume (0.1× avg).
Summary
Young Pharmaceuticals disclosed a 5.22% open-market stake in Azitra (~$344,000) and said it will push the board and management on stockholder-value initiatives, including possible business combinations and board changes.
Key Events · Ownership and Investor Activity · AZTR
-
5.22% Stake Disclosed
Young Pharmaceuticals, Inc. beneficially owns 316,300 Azitra shares, or 5.22% of the 6,060,435 shares outstanding per the November 12, 2026 10-Q.
-
Open-Market Accumulation
The stake was built through open-market purchases totaling approximately $343,977.15, including 238,500 post-split shares bought in the past 60 days for approximately $198,992.70 at $0.698–$1.4390 per share.
-
Activist Intent Stated
The filer says it intends to communicate with the board and management on enhancing stockholder value and may discuss business combinations, board composition and capitalization changes.
-
Strategic Buyer Profile
Young Pharmaceuticals is itself a developer and marketer of dermatological and aesthetic skincare products, making the stake potentially strategic rather than purely financial.
Analysis · AZTR · Life Sciences
A dermatology and aesthetic skincare company has just disclosed a 5.22% stake in Azitra, bought entirely in the open market for roughly $344,000, and it explicitly says it will engage the board and management on ways to enhance stockholder value — including possible business combinations, board composition and capitalization changes. That turns a passive holder into a potential activist voice at a company that just reported a $2.95M quarterly net loss, $3.75M of cash and going-concern doubt. Because the buyer is a strategic operator in the same skincare space, the stake could precede a partnership or a deal rather than just a financial trade. The purchases were made at $0.70–$1.44 per share, well above today's $0.63, meaning the buyer is already underwater on the position.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZTR was trading at $0.63 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $0.52 to $5.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.